Navigation Links
Henry Ford researchers identify genetic factors that may aid survival from brain cancer
Date:5/12/2014

DETROIT A Henry Ford Hospital research team has identified specific genes that may lead to improved survival of glioblastoma, the most common and deadly form of cancerous brain tumor.

The molecular data is expected to aid further research into genes that either help or impede the survival of patients diagnosed with the tumor, which can invade and rapidly grow in any part of the human brain.

"Studies such as ours that help define molecular alterations associated with short-term survival likely will help define the reasons why our current treatments don't succeed in these patients," says Dr. Steven Kalkanis, M.D., a neurosurgeon and surgical oncologist at Henry Ford's Hermelin Brain Tumor Center, and lead author of the study.

"As new mechanisms of resistance are revealed and targeted agents are developed to address these mechanisms, the number of long-term survivors should increase."

The Henry Ford study was published this month in the journal Clinical Neurology and Neurosurgery.

The study focused on 476 patients at Henry Ford Hospital who were diagnosed with glioblastoma from 1995 to 2008. Each was randomly chosen from the Hermelin Center's brain tumor tissue bank, which holds more than 4,100 unique patient brain tumor specimens.

The patients were evaluated as part of the international Cancer Genome Atlas, to which the Hermelin Brain Tumor Center at Henry Ford Hospital was a major contributor.

Besides noting a steady rise in survival rates over the 14 years examined in the study, researchers found that the median survival time among this group rose from 11.8 months in patients diagnosed from 1995 to 1999 to 15.9 months in those diagnosed from 2005 to 2008.

After categorizing each patient as a short (less than nine months), medium (nine to 24 months) or long-term (at least 24 months) survivor, the researchers looked for relationships between survival time and patient age, gender, functional
'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-850-3471
Henry Ford Health System
Source:Eurekalert

Page: 1 2

Related biology news :

1. Indiana University associate professor earns APSs Henry Pickering Bowditch Award
2. Oregon researchers capture handoff of tracked object between brain hemispheres
3. Homemade stink bug traps squash store-bought models, Virginia Tech researchers find
4. Ban cigarette filters to save the environment, suggest researchers
5. University of Toronto researchers find seeing Jesus in Toast phenomenon perfectly normal
6. Researchers find unique fore wing folding among Sub-Saharan African Ensign wasps
7. Penn State researchers believe ants can offer human-disease insights
8. Researchers find way to decrease chemoresistance in ovarian cancer
9. Researchers receive top honors for ecology paper
10. Researchers find the accelerator for molecular machines
11. Clemson researchers help track mysterious, endangered little devil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Grand Canyon may be so old that dinosaurs once lumbered ... the University of Colorado at Boulder and the California Institute ... radiometric dating to show the Grand Canyon may have formed ... origins by 40 million to 50 million years. The ...
... researchers is needed to make progress towards one ... marks contribute to regulation of gene expression. This ... European Science Foundation (ESF), Computational Approaches to the ... Epigenetics studies features of the DNA and chromatin ...
... NEW YORK, April 9 e-Smart(R) Technologies,Inc. ... and its parent,company, IVI Smart Technologies, Inc., ... filed in a Motion last month by,IDsmart ... Northern District of,California, San Francisco Division, Case ...
Cached Biology News:Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3Computation to unravel how genes are regulated and shed light on how cells become different 2Computation to unravel how genes are regulated and shed light on how cells become different 3IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 2IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 3
(Date:10/25/2014)... Des Moines, Iowa (PRWEB) October 24, 2014 ... today that Perdue plans to more than double ... in 2015 in geographies supplying its soybean crush ... oil produced from this program will target several ... healthier oil alternatives with good performance. , For ...
(Date:10/25/2014)... 24, 2014 A new way to ... pitfalls of current skin grafting technologies, it also speeds ... The method, outlined in the October issue of STEM ... deep skin injuries that result from severe burns and ... the skin’s regenerative elements. These wounds heal by contraction, ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... July 10 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... European Medicines Agency (EMEA) for ranolazine for,the treatment of ... (EU),member states. This approval follows a positive opinion from ... on April 24, 2008., Ranolazine is approved for ...
... MADISON, N.J., July 10 Quest Diagnostics,Incorporated (NYSE: ... and services, announced today that its second-quarter,2008 results will ... market,opens, and that it will hold its quarterly conference ... a.m. ET on that day., The public may ...
... Inc. (Nasdaq: ALXN ), today announced that the ... on Tuesday, July 29, 2008, at,10:00 a.m. Eastern Time ... for the second quarter ended June 30, 2008. Alexion,anticipates ... Tuesday,July 29, 2008., To participate in this conference ...
Cached Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
... First-Strand cDNA Labeling System - dCTP ... reactions. For the generation and purification ... are packaged together for complete cDNA ... can be used for performing labeling ...
... CyScribe Post-Labeling Kit with CyScribe ... the generation and purification of Cy3- ... together for complete cDNA labeling and ... used for performing labeling reactions with ...
NORMAL DONOR DONKEY SERUM...
Biology Products: